1. Introduction {#sec1-marinedrugs-18-00129}
===============

Since the discovery of antibacterial penicillin from *Penicillium notatum*, there have been tremendous achievements with regard to the development of fungal drugs \[[@B1-marinedrugs-18-00129]\]. The antifungal medicine griseofulvin, which was initially isolated from *Penicillium griseofulvum*, has been applied for the treatment of ringworm in skin and nails in animals and humans \[[@B2-marinedrugs-18-00129]\]. Lovastatin, the first commercial statin isolated from a fermentation broth of *Aspergillus terreus*, has been used to treat high blood cholesterol and reduce the risk of cardiovascular disease \[[@B3-marinedrugs-18-00129]\]. The immunosuppressant agent cyclosporine was isolated from the fungus *Tolypocladium inflatum* \[[@B4-marinedrugs-18-00129]\]. Endophytic fungi occur in all plants investigated up to now and are important for the fitness and survival of their hosts \[[@B5-marinedrugs-18-00129]\]. The chemically remarkably creative fungal genus *Pestalotiopsis* contains around 234 described fungal species listed in Index Fungorum, including 44 taxol producers \[[@B6-marinedrugs-18-00129],[@B7-marinedrugs-18-00129]\]. *Pestalotiopsis* has attracted considerable attention due to the abundance and diversity of secondary products found in members of this genus \[[@B8-marinedrugs-18-00129],[@B9-marinedrugs-18-00129]\]. Pestalachloride A, a new chlorinated benzophenone alkaloid produced by *Pestalotiopsis adusta*, showed potent antifungal activity against *Fusarium culmorum* with an IC~50~ value of 0.89 μM \[[@B10-marinedrugs-18-00129]\]. The first chlorinated pupukeanane derivative, chloropupukeananin, which was isolated from fermentation broth of *Pestalotiopsis fici*, inhibited HIV-1 replication in C8166 cells with an IC~50~ value of 14.6 μM \[[@B11-marinedrugs-18-00129]\]. Pestaloquinols A and B, two unique isoprenylated epoxyquinol derivatives obtained from rice cultures of *Pestalotiopsis* sp., both exhibited cytotoxicity against HeLa cell line with IC~50~ values of 8.8 μM \[[@B12-marinedrugs-18-00129]\]. Pestalotines A and B, two novel phytotoxic *γ*-lactonic dimers from *Pestalotiopsis* sp., showed potent phytotoxicity against the radical growth of *Echinochloa crusgalli* with IC~50~ values of 0.19 and 0.25 μM, respectively \[[@B13-marinedrugs-18-00129]\].

In previous studies from our group, cytotoxic 14-membered macrolides were obtained from the mangrove-derived fungus *Pestalotiopsis microspora* with IC~50~ values ranging from 0.7 to 5.6 μM \[[@B14-marinedrugs-18-00129]\]. In the present study, the endophytic fungus *Pseudopestalotiopsis theae*, which was previously reported as *Pestalotiopsis theae* and taxonomically revised in 2014 \[[@B7-marinedrugs-18-00129]\] was isolated from roots of the mangrove plant *Rhizophora racemosa* collected around Lagos, Nigeria. Fermentation of this fungus on solid rice medium yielded eighteen new polyketides, namely pestalotheols I--Q (**1**--**9**) ([Supplementary information](#app1-marinedrugs-18-00129){ref-type="app"}) and cytosporins O--W (**15**--**23**), in addition to eight known congeners ([Figure 1](#marinedrugs-18-00129-f001){ref-type="fig"}). In this paper, the isolation, structure elucidation, and bioactivity of all isolated compounds are reported.

2. Results and Discussion {#sec2-marinedrugs-18-00129}
=========================

Compound **1** was obtained as yellowish gel. The molecular formula of **1** was determined as C~16~H~24~O~5~ by HRESIMS data, indicating five degrees of unsaturation. The ^13^C NMR data ([Table 1](#marinedrugs-18-00129-t001){ref-type="table"}) for **1** revealed the presence of a carbonyl at *δ*~C~ 191.9 (C-10), four olefinic carbons at *δ*~C~ 153.7 (C-12), 138.7 (C-7), 138.0 (C-6), and 120.7 (C-11), five oxygenated carbons at *δ*~C~ 84.2 (C-2), 77.8 (C-4), 76.3 (C-9), 70.8 (C-15), and 68.9 (C-5), two methylene groups at *δ*~C~ 34.0 (C-3) and 25.7 (C-8), together with four methyls at *δ*~C~ 27.2 (C-14), 25.9 (C-17), 25.8 (C-16), and 20.5 (C-13), accounting for three degrees of unsaturation. Thus, compound **1** was suggested to be bicyclic in nature. The COSY correlations between H-2/H-3ab, OH-5/H-5/H-6, H-8/H-9, together with the HMBC correlations from H-2 to H-9, from OH-4 to C-3, C-4, C-5, and C-9, from H-5 to C-4 and C-9, from H-6 to C-4 and C-8, and from H-8ab to C-4, C-6, C-7, and C-9, established the presence of a tetrahydrofuranocyclohexene moiety with two hydroxy groups at C-4 and C-5. Additional HMBC correlations from Me-14 to C-11, C-12, and C-13, and from H-11, H-6 and H-8a to C-10 indicated the attachment of a 3-methyl-1-oxobut-2-en-1-yl side chain at C-7. Moreover, the location of a 2-hydroxyisopropyl subunit at C-2 was confirmed by the HMBC correlations from Me-16(17) to C-2, C-15 and C-17(16), and from OH-15 to C-2, C-15, C-16, and C-17. Thus, the planar structure of **1** was established as shown. The relative configuration of **1** was elucidated by coupling constants and NOE correlations ([Figure 2](#marinedrugs-18-00129-f002){ref-type="fig"}). The large values of *J*~H-2/H-3a~ (9.9 Hz) and *J*~H-9/H-8b~ (10.7 Hz) suggested trans-diaxial orientation of these protons. The NOE correlations from H-9 to Me-16, H-3a, OH-5, and H-8a, and between H-3a and OH-5 indicated these protons to be on the same side, whereas the NOE correlations from OH-4 to H-2, H-3b, H-5, and H-8b confirmed they were in opposite orientation. Based on the summarized results ([Figure 3](#marinedrugs-18-00129-f003){ref-type="fig"}) of the modified Mosher's method, the absolute configuration of C-5 was determined to be *S*, thereby assigning 2*R*, 4*R*, 5*S*, 9*S* absolute configuration for pestalotheol I (**1**).

Based on the HRESIMS result as well as 1D and 2D NMR data ([Table 1](#marinedrugs-18-00129-t001){ref-type="table"}), the gross structure of **2** was elucidated as being identical to that of **1**. However, different NOE relationships were observed in the ROESY spectrum of **2** compared to **1** ([Figure 2](#marinedrugs-18-00129-f002){ref-type="fig"}). The NOE correlations between H-9/H-8b, H-9/H-5, H-9/OH-4, OH-4/H-5, OH-4/H-3b indicated that these protons were on the α-face, whereas the NOE correlations from H-2 to H-3a and H-8a indicated they were β-oriented. Thus, the absolute configuration of **2** was tentatively assigned as 2*R*, 4*S*, 5*R*, 9*S* in comparison to **1**.

Pestalotheol K (**3**) has the molecular formula C~16~H~24~O~5~, containing one additional oxygen atom compared to truncateol Q, a polyketide analog isolated from *Truncatella angustata* \[[@B15-marinedrugs-18-00129]\]. The NMR data of **3** ([Table 1](#marinedrugs-18-00129-t001){ref-type="table"}) were similar to those of truncateol Q, except for the replacement of an olefinic methyl by an oxygenated methylene moiety at *δ*~C~ 60.9 and *δ*~H~ 4.21 and 4.16 (CH-13) and a hydroxy group at *δ*~H~ 3.70 (t, OH-13). The COSY correlation between OH-13/H-13ab and the HMBC correlations from H-13ab to C-11 (*δ*~C~ 122.8), C-12 (*δ*~C~ 139.9), and C-14 (*δ*~C~ 22.0) confirmed the location of this additional oxygenated methylene moiety at C-13. The remaining substructure and relative configuration of **3** were elucidated to be identical to truncateol Q after detailed analysis of the 2D NMR spectroscopic data of **3**.

The NMR data ([Table 2](#marinedrugs-18-00129-t002){ref-type="table"}) of pestalotheol L (**4**) were similar to those of truncateol K, a known polyketide containing a chloride atom at C-4 \[[@B16-marinedrugs-18-00129]\]. The molecular formula of **4** was determined as C~16~H~22~O~5~ by HRESIMS, suggesting the replacement of the chlorine atom at C-4 by a hydroxy group in **4**, which was supported by the observation of four hydroxy groups at *δ*~H~ 5.08, 5.05, 4.77, and 4.31 in the ^1^H NMR spectrum of **4** rather than three signals of hydroxy groups in truncateol K. On the basis of the 2D NMR spectroscopic data of **4**, the remaining substructure and relative configuration of **4** were determined to be identical to truncateol K.

Compound **5** has the same planar structure as **4** based on the 1D and 2D NMR spectroscopic data as well as on the HRESIMS data of **5**. However, the NOE interactions of **5** differed from those of **4** as also observed between **1** and **2**. In the ROESY spectrum of **5**, correlations from H-9 to Me-16, H-3a and OH-5, and from OH-5 to H-3a and H-6 were found, indicating they were on the same side. On the other hand, the NOE correlations between H-3b/H-2, H-2/OH-4, OH-4/H-5, H-5/OH-6 placed those protons on the other side of the ring. Hence the relative configuration of **5** was elucidated as 2*R\**, 4*R\**, 5*S\**, 6*R\**, 9*S\** whereas that of **4** was 2*R\**, 4*S\**, 5*R\**, 6*R\**, 9*S\**.

The molecular formula of pestalotheol N (**6**) was deduced as C~16~H~24~O~5~ from the HRESIMS data. The NMR data ([Table 2](#marinedrugs-18-00129-t002){ref-type="table"}) of **6** were compatible with those of the co-isolated known compound truncateol H (**12**) except for the lack of the chloride atom at C-5 \[[@B16-marinedrugs-18-00129]\]. Instead, the COSY correlation between the D~2~O changeable proton at *δ*~H~ 5.28 and H-5 (*δ*~H~ 3.83) suggested C-5 to be hydroxylated. Similar NOE interactions were observed for **6** and **12**, indicating the relative configuration of **6** to be identical to that of **12**, for which the absolute configuration had previously been determined by Mosher's reaction and by the X-ray data of its 6-epimer \[[@B16-marinedrugs-18-00129]\].

Pestalotheol O (**7**) was obtained as colorless oil. The molecular formula of **7** was determined as C~18~H~26~O~6~ by HRESIMS, containing an additional acetyl group when compared to **6**, which was further supported by the presence of a carbonyl carbon at *δ*~C~ 169.2 and a methyl group at *δ*~C~ 20.5 and *δ*~H~ 2.09 in the NMR data of **7** ([Table 3](#marinedrugs-18-00129-t003){ref-type="table"}). The location of this additional acetyl group at C-5 was evident from the HMBC correlation from H-5 (*δ*~H~ 5.01) to the carbonyl carbon of the acetyl group. Analysis of 1D and 2D NMR data of **7** concluded its remaining substructure to be the same as **6**. The absolute configuration of C-6 in **7** was determined as *R* by comparison of chemical shifts between its methoxyphenylacetic acid (MPA) esters ([Figure 3](#marinedrugs-18-00129-f003){ref-type="fig"}).

Based on the HRESIMS data, the molecular formula of compound **8** was deduced as C~16~H~25~O~7~, containing one additional oxygen atom when compared to the coisolated known derivative, pestalotheol A (**13**) \[[@B17-marinedrugs-18-00129]\]. The COSY correlation between the D~2~O changeable proton at *δ*~H~ 4.30 and H-11 (*δ*~H~ 4.13) and the HMBC correlations from H-11 to C-10, C-12, C-13, and C-14 confirmed the replacement of the methylene group by a hydroxy group at C-11 in **8**. Compounds **8** and **13** share the same relative configuration at C-2, C-4, C-5, and C-9 as evident from their similar coupling constants and NOE relationships. Moreover, Mosher's method was applied to determine the absolute configuration at C-5 and C-11 of **8**. Due to the influence of multiple MPA moieties, anomalous ∆*δ* values were observed for Me-13 (−0.27) and Me-14 (+0.06). The absolute configuration at C-5 and C-11 of **8** was tentatively assigned as *R* ([Figure 3](#marinedrugs-18-00129-f003){ref-type="fig"}). Therefore, the 2*R*, 4*R*, 5*R*, 9*S,* and 11*R* absolute configuration was assigned for pestalotheol P (**8**).

The HRESIMS of pestalotheol Q (**9**) showed the pseudomolecular ion peak at 355.1754 \[M + H\]^+^, indicating the molecular formula of C~18~H~27~O~7~. The UV spectrum and the NMR data of **9** suggested it to be an analog of pestalotheol A \[[@B17-marinedrugs-18-00129]\], with addition of an acetyl group as evident from signals in the ^1^H and ^13^C NMR spectroscopic data at *δ*~H~ 2.09, *δ*~C~ 169.5 and 20.5. The HMBC correlations from H-5 (*δ*~H~ 5.28) to the carbonyl carbon of the acetyl group indicated the attachment of the acetyl group at C-5. Based on the similar coupling constants and NOE relationships, the relative configuration of **9** was suggested to be identical to that of **13**. Thus, pestalotheol Q (**9**) was elucidated to be 5-acetoxy derivative of pestalotheol A (**13**).

Cytosporin O (**15**) was obtained as yellowish gel. The molecular formula of **15** was established as C~19~H~32~O~5~ from the HRESIMS data, indicating four degrees of unsaturation. The ^13^C NMR data ([Table 4](#marinedrugs-18-00129-t004){ref-type="table"}) displayed signals of four olefinic carbons at *δ*~C~ 133.8 (C-8), 132.1 (C-15), 132.0 (C-9), and 126.0 (C-14), accounting for two degrees of unsaturation. Therefore, **15** was suggested to contain a bicyclic skeleton. In addition, six oxygenated carbons at *δ*~C~ 74.9 (C-2), 70.6 (C-3), 70.0 (C-10), 69.3 (C-5), 63.9 (C-7), and 57.7 (C-13), and three methyls at *δ*~C~ 27.9 (C-11), 16.1 (C-12), and 13.9 (C-20) were observed. Upon analysis of the 1D and 2D NMR data, **15** was suggested to be a derivative of cytosporin D \[[@B18-marinedrugs-18-00129]\] except for the replacement of signals of the epoxy ring at C5/C6 by an additional D~2~O exchangeable proton at *δ*~H~ 5.07 (s, OH-5) and an additional methylene group at *δ*~C~ 35.7, and *δ*~H~ 2.00, 1.54 (CH~2~-6). The HMBC correlations from OH-5 to C-4, C-5, C-6, and C-10, together with the COSY correlations between H-6ab and H-7, indicated a hydroxy group at C-5 and a methylene group at C-6. Thus, the planar structure of **15** was established as shown. The large coupling constant (15.7 Hz) revealed *E*-geometry of the double bond at C-15/C-16. The NOE interactions between H-10/OH-5, OH-5/H-4b, H-4b/H-10, H-10/Me-12, Me-12/H-4b indicated those protons to be orientated on the same side, whereas the NOE correlations between Me-11/H-3, H-3/H-4a, H-3/H-6a, H-6a/H-7 supported them to be on the opposite side ([Figure 4](#marinedrugs-18-00129-f004){ref-type="fig"}).

Compound **16** has the molecular formula C~19~H~32~O~6~ as deduced from the sodium adduct ion at *m*/*z* 379.2094 \[M + Na\] ^+^ in HRESIMS, containing an additional oxygen atom when compared to **15**. The NMR data ([Table 4](#marinedrugs-18-00129-t004){ref-type="table"}) of **16** resembled those of **15** except for the replacement of a methylene group by an oxygenated methine at *δ*~C~ 75.3 and *δ*~H~ 3.55 (CH-6). The presence of an additional D~2~O exchangeable proton at *δ*~H~ 3.98 and its COSY correlation with H-6 indicated a hydroxy group at C-6. Therefore, **16** was elucidated as 6-hydroxylated derivative of cytosporin O (**15**). The relative configuration at C-3, C-5, C-7, and C-10 in **16** was determined to be identical to that of **15** by comparison of their coupling constants and NOE relationships. In addition, the NOE correlations from OH-6 to H-3 and H-7, and from H-6 to 5-OH and 7-OH confirmed α-orientation of OH-6 in **16**.

The HRESIMS as well as 1D and 2D NMR data of cytosporin Q (**17**) suggested that it possessed the same planar structure as the known cytosporin D bearing an epoxy ring at C-5/C-6 \[[@B18-marinedrugs-18-00129]\]. The NOE correlations observed in **17** between H-10/Me-12, Me-12/H-4a, H-4a/H-10, and between Me-11/H-3, H-3/H-4b, H-4b/H-6, indicated that **17** shared the same relative configuration at C-3, C-5, C-6, and C-10 as cytosporin D. However, the relative configuration at C-7 could not be determined by NOE relationships or *J* values. Therefore, the modified Mosher's method was applied to determine the absolute configuration at C-3 and C-7 of **17**. In order to exclude the influence of the primary alcohol at C-13, 4,4′-dimethoxytrytil chloride (DMT-Cl) was used for protection before Mosher's reaction, yielding compound **17a**. Meanwhile, Mosher's reaction was also conducted with the coisolated known compound cytosporin F (**26**) \[[@B19-marinedrugs-18-00129]\], bearing an acetyl group attached to C-13. The differences in chemical shifts of (*R*)- and (*S*)-MPA esters assigned 3*R* and 7*R* absolute configuration for both **17a** and cytosporin F (**26**) ([Figure 3](#marinedrugs-18-00129-f003){ref-type="fig"}). Thus, **17** was identified as 7-epimer of cytosporin D and has the absolute configuration of 3*R*, 5*S*, 6*R*, 7*R,* and 10*R*. Cytosporin D had been firstly reported from the fungus *Eutypella scoparia* derived from a marine pulmonate mollusk \[[@B18-marinedrugs-18-00129]\], while cytosporins F--K were produced by *Pestalotiopsis theae*, an endophyte from leaves of *Turraeanthus longipes* \[[@B19-marinedrugs-18-00129]\]. From biogenetic considerations and the results of Mosher's reaction, it is reasonable to revise the absolute configurations of cytosporins F--K \[[@B19-marinedrugs-18-00129]\] as 3*R*, 5*S*, 6*R*, 7*R,* and 10*R*, the same as **17** rather than that of cytosporin D.

The molecular formula of cytosporin R (**18**) was determined as C~19~H~30~O~6~ by HRESIMS, with an additional oxygen atom compared to cytosporin Q (**17**). A methyl doublet at *δ*~H~ 1.03 (Me-20) was found in the ^1^H NMR data of **18** instead of a methyl triplet in **17** ([Table 5](#marinedrugs-18-00129-t005){ref-type="table"}). Detailed examination of the 2D NMR spectroscopic data revealed **18** to be the 19-OH substituted analog of cytosporin Q (**17**). Similar NOE interactions were observed in **18** as for **17**, indicating that both compounds shared the same relative configuration regarding the ring system. Due to the low amount, cytosporin R (**18**) was subjected for Mosher's method directly without protecting the primary alcohol at C-13. The absolute configuration at C-19 of side chain was determined as *S* ([Figure 3](#marinedrugs-18-00129-f003){ref-type="fig"}). From biogenetic considerations, the remaining stereocenters of **18** are assumed to share the same absolute configuration as cytosporin Q (**17**).

Compound **19** has the same molecular formula of C~19~H~30~O~6~ as cytosporin R (**18**) as determined by the HRESIMS data. After detailed analysis of the 1D and 2D NMR spectroscopic data of **19**, both compounds were found to differ in the position of the hydroxy group in the side chain. The COSY correlations between the D~2~O exchangeable proton at *δ*~H~ 4.34 and H-17 (*δ*~H~ 3.46), and between H-14/H-15/H-16ab/H-17 confirmed that C-17 was hydroxylated in **19**. Therefore, compound **19** was suggested to be the C-17 epimer of cytosporin K (**25**) \[[@B19-marinedrugs-18-00129]\]. Similar NOE correlations were observed in **19** and **25**, suggesting that both compounds share the same relative configuration regarding the bicyclic ring core. Due to the low amount of cytosporin S (**19**), Mosher's reaction was carried out for its 17-epimer cytosporin K (**25**) \[[@B19-marinedrugs-18-00129]\], whose absolute configuration in the side chain was uncertain before. Comparison of the chemical shifts of (*R*)- and (*S*)-MPA esters of **25** ([Figure 3](#marinedrugs-18-00129-f003){ref-type="fig"}) suggested 17*S* absolute configuration for cytosporin K (**25**). Thus, 17*R* absolute configuration was proposed for cytosporin S (**19**).

Cytosporins T and U (**20** and **21**) have the same molecular formula of C~19~H~30~O~6~ as deduced by the HRESIMS data. Their NMR data ([Table 5](#marinedrugs-18-00129-t005){ref-type="table"} and [Table 6](#marinedrugs-18-00129-t006){ref-type="table"}) were comparable to those of **19**. However, the olefinic proton at H-15 appeared as dd in **20** and **21** rather than as dt in **19**, suggesting the hydroxy group in the side chain to be located at C-16 in **20** and **21** rather than at C-17 in **19**. This was further supported by the COSY correlations observed between H-14/H-15/H-16/H-17ab, as well as between H-17 and a D~2~O exchangeable proton in **20** and **21**. Detailed analysis of the 2D NMR spectroscopic data of **20** and **21** revealed that the remaining substructure was identical to that of **19**. Cytosporins T and U (**20** and **21**) only differ in the absolute configuration in the side chain, as found for **19** and **25**. The absolute configuration at C-16 of both compounds was not determined due to the low amounts.

The NMR data of compound **22** were similar to those of cytosporin F(**26**) \[[@B19-marinedrugs-18-00129]\], and both compounds have the same molecular formula as evident from the HRESIMS data. However, the shielded methylene group at C-13 (*δ*~C~ 57.6, *δ*~H~ 4.11 and 3.78 in **22** vs. *δ*~C~ 63.2, *δ*~H~ 4.74 and 4.67 in **26**), and the deshielded oxygenated methine at C-7 (*δ*~H~ 5.85 in **22** vs. *δ*~H~ 4.63 in **26**) in **22** suggested that the acetoxy moiety was attached at C-7 in **22** rather than at C-13 in **26**, which was further confirmed by the HMBC correlation from H-7 to the carbonyl carbon (*δ*~C~ 170.0) of the acetoxy moiety. The remaining substructure of **22** was elucidated to be identical to that of **26**. Based on the similar NOE correlations and the biogenetic relationship between **22** and **26**, compound **22** was suggested to share the same 3*R*, 5*S*, 6*R*, 7*R,* and 10*R* absolute configuration as **26**.

The molecular formula C~19~H~28~O~5~ was suggested for cytosporin W (**23**) by the HRESIMS data, indicating an additional degree of unsaturation when compared to **17**. The absence of one D~2~O changeable proton in the ^1^H NMR data ([Table 6](#marinedrugs-18-00129-t006){ref-type="table"}), along with the HMBC correlations from H-6 (*δ*~H~ 3.54) and H-14 (*δ*~H~ 6.04) to a carbonyl carbon at *δ*~C~ 195.8 indicated a ketone carbonyl to be located at C-7, which accounted for the additional degree of unsaturation. The remaining structure including the relative configuration was determined to be identical to that of **17** after detailed analysis of the 2D NMR spectroscopic data of **23**.

The remaining known compounds were identified as truncateols B (**10**), D (**11**), and H (**12**) \[[@B16-marinedrugs-18-00129]\], pestalotheols A (**13**) and D (**14**) \[[@B17-marinedrugs-18-00129]\], cytosporins J (**24**), K (**25**), and F (**26**) \[[@B19-marinedrugs-18-00129]\]. Both new compounds pestalotheol O (**7**) and Q (**9**) contain acetoxyl group at C-5. In order to exclude the possibility that they might be artifacts formed during the extraction with EtOAc, relative compounds pestalotheol N (**6**) and pestalotheol A (**13**) were incubated in EtOAc for 48 h at room temperature. Unchanged retention time and molecular weight from HPLC together with MS results indicated that they were natural products rather than artifacts.

In previous report, cytosporins A--C were known as angiotensin II binding inhibitors \[[@B20-marinedrugs-18-00129]\], while cytosporin L was active against the bacteria *Micrococcus lysodeikticus* and *Enterobacter aerogenes* with MIC values of 3.12 µM \[[@B21-marinedrugs-18-00129],[@B22-marinedrugs-18-00129]\]. In the present study, all isolated compounds were tested for their cytotoxicity and antibacterial activity. Only compound **23**, with a carbonyl group at C-7 instead of a hydroxy group, showed significant cytotoxicity against the mouse lymphoma cell line L5178Y with an IC~50~ value of 3.0 μM, even stronger than that of the positive control kahalalide F (IC~50~ 4.3 μM), whereas the other compounds were not active (IC~50~ \> 20 μM), suggesting the importance of α,β-unsaturated ketone moiety in **23** for cytotoxicity. In the antibacterial activity assay, none of the isolated compounds were active against the Gram-positive bacteria *Staphylococcus aureus* (ATCC 29213) and *Mycobacterium tuberculosis* (H37Rv) and the Gram-negative bacterium *Pseudomonas aeruginosa* (ATCC 27853) and drug-resistant *Acinetobacter baumannii* (ATCC BAA-1605) (MIC \> 100 µM). However, in combination with a sublethal colistin concentration of 0.1 µM, compounds **22** and **23** displayed antibacterial activity against drug-resistant *Acinetobacter baumannii* (ATCC BAA-1605) with MIC values of 50 and 100 µM, respectively.

3. Materials and Methods {#sec3-marinedrugs-18-00129}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-18-00129}
------------------------------------

Optical rotations were measured with a Jasco P-2000 polarimeter (JASCO, Tokyo, Japan). Analytical HPLC was performed with a Dionex UltiMate-3400SD system coupled to an LPG-3400SD pump and a DAD300RS photodiode array detector (Dionex Softron, Germering, Germany). The analytical column (125 × 4 mm) was prefilled with Eurosphere-10 C18 (Knauer, Berlin, Germany), following the program: 0 min (10% MeOH); 5 min (10% MeOH); 35 min (100% MeOH); 45 min (100% MeOH). NMR spectra were recorded with Bruker ARX 300 or 600 NMR spectrometers (Bruker, Karlsruhe, Germany). Chemical shifts were referenced to the solvent residual peaks. HRESIMS were recorded on a UHR-QTOF maXis 4G mass spectrometer (Bruker Daltonics, Bremen, Germany). Column chromatography was conducted with Merck MN silica gel 60M (0.04--0.063 mm). TLC plates precoated with silica gel F~254~ (Merck) were used with detection under 254 and 366 nm. Distilled and spectral grade solvents were used for column chromatography and spectroscopic measurements, respectively. Semipreparative HPLC was performed using a Merck Hitachi HPLC System (UV detector L-5410; pump L-5100; Eurosphere-100 C18, 300 × 8 mm), with a mixture of MeOH-H~2~O or MeCN-H~2~O as mobile phase.

3.2. Fungal Material {#sec3dot2-marinedrugs-18-00129}
--------------------

The fungus was isolated from roots of the mangrove plant Rhizophora racemosa collected around Lagos in October 2017. It was identified as *Pseudopestalotiopsis theae* (GenBank accession number MN814071) by DNA amplification and sequencing of its ITS region as described before \[[@B23-marinedrugs-18-00129]\].

3.3. Fermentation, Extraction, and Isolation {#sec3dot3-marinedrugs-18-00129}
--------------------------------------------

The fungus was cultivated on solid rice medium in 10 Erlenmeyer flasks (1 L with 100 g rice and 110 mL demineralized water per flask, autoclaved at 121 °C for 20 min before inoculation). EtOAc (700 mL) was added to each flask after fermentation of 14 days at 20 °C. The fungal cultures were subjected to shaking at 140 rpm for 8 h following addition of EtOAc. After removal of the solvent under reduced pressure, the obtained residue (12.4 g) was subjected to liquid--liquid partition between *n*-hexane and MeOH. After HPLC analysis of both phases, only the methanolic phase was further chromatographically investigated.

The MeOH fraction (8.1 g) was subjected to a vacuum liquid silica gel column chromatography using a gradient solvent system of *n*-hexane and EtOAc (100:1 to 0:100; *v/v*) to obtain seven fractions (Fr. 1--7). Following Sephadex LH-20 column (60 × 3 cm) chromatography with MeOH as mobile phase, Fr. 3 (1.8 g) was separated into four subfractions (Fr. 3.1--3.4). Fr. 3.4 (0.6 g) was then subjected to vacuum liquid RP-18 column (60 × 200 mm) chromatography using a solvent gradient (from 100% H~2~O to 100% MeOH) to give five subfractions (Fr.3.4.1--3.4.5). Compounds **6** (4.0 mg), **7** (2.5 mg), **9** (2.2 mg), **10** (5.0 mg), **11** (15 mg),**12** (1.9 mg), **14** (1.7 mg), **22** (3.1 mg), and **23** (2.9 mg) were obtained by semipreparative HPLC (MeOH-H~2~O: 0--2 min, 40%; 2--27 min, from 40% to 60%; 27--32 min, 100%) from Fr.3.4.1 (110 mg). Fr. 4 (2.7g) was subjected to vacuum liquid RP-18 column chromatography (60 × 200 mm) using a solvent gradient (from 100% H~2~O to 100% MeCN) to give seven subfractions (Fr. 4.1--4.7). Compounds **1** (2.5 mg), **2** (1.6 mg), **4** (3.0 mg), **5** (1.4 mg), **18** (3.7 mg), and **24** (5.8 mg) were obtained by semipreparative HPLC (MeCN-H~2~O: 0--2 min, 8%; 2--22 min, from 8% to 20%; 22--30 min, 100%) from Fr.4.3 (210.0 mg), while compounds **15** (3.3 mg), **16** (3.0 mg), **17** (37.2 mg), and **26** (13.0 mg) were obtained by semipreparative HPLC (MeOH-H~2~O: 0--2 min, 30%; 2--22 min, from 30% to 60%; 22--30 min, 100%) from Fr.4.6 (200.0 mg). Following similar procedures, Fr. 5 (1.8 g) was also separated by vacuum liquid RP-18 column (60 × 200 mm) chromatography to give four subfractions (Fr.5.1--Fr.5.4). Compounds **13** (3.5 mg), **19** (1.5 mg), **20** (1.3 mg), **21**(3.8 mg), and **25** (6.2 mg) were obtained from Fr. 5.3 (130 mg) by semipreparative HPLC (MeOH-H~2~O: 0--2 min, 38%; 2--22 min, from 38% to 58%; 22--30 min, 100%), while compounds **3** (2.5 mg) and **8** (4.1 mg) were obtained by semipreparative HPLC (MeCN-H~2~O: 0--2 min, 5%; 2--22 min, from 5% to 15%; 22--30 min, 100%) from Fr. 5.4 (68.0 mg).

*Pestalotheol I* (1): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ +115 (*c* 0.25, MeOH); UV (MeOH) λ~max~ 219 nm; ^1^H and ^13^C NMR data, [Table 1](#marinedrugs-18-00129-t001){ref-type="table"}; HRESIMS *m/z* 297.1694 \[M + H\]^+^ (C~16~H~25~O~5~, calcd. 297.1697), 319.1513 \[M + Na\]^+^ (C~16~H~24~O~5~Na, calcd. 319.1516).

*Pestalotheol J* (**2**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ −12 (*c* 0.20, MeOH); UV (MeOH) λ~max~ 268 nm; ^1^H and ^13^C NMR data, [Table 1](#marinedrugs-18-00129-t001){ref-type="table"}; HRESIMS *m/z* 297.1700 \[M + H\]^+^ (C~16~H~25~O~5~, calcd. 297.1702).

*Pestalotheol K* (**3**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ +111 (*c* 0.25, MeOH); UV (MeOH) λ~max~ 246 nm; ^1^H and ^13^C NMR data, [Table 1](#marinedrugs-18-00129-t001){ref-type="table"}; HRESIMS *m/z* 297.1700 \[M + H\]^+^ (C~16~H~25~O~5~, calcd. 297.1702).

*Pestalotheol L* (**4**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ −60 (*c* 0.30, MeOH); UV (MeOH) λ~max~ 260 nm; ^1^H and ^13^C NMR data, [Table 2](#marinedrugs-18-00129-t002){ref-type="table"}; HRESIMS *m/z* 317.1362 \[M + Na\]^+^ (C~16~H~22~O~5~Na, calcd. 317.1359).

*Pestalotheol M* (**5**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ +17 (*c* 0.25, MeOH); UV (MeOH) λ~max~ 262 nm; ^1^H and ^13^C NMR data, [Table 2](#marinedrugs-18-00129-t002){ref-type="table"}; HRESIMS *m/z* 317.1360 \[M + Na\]^+^ (C~16~H~22~O~5~Na, calcd. 317.1359).

*Pestalotheol N* (**6**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ +47 (*c* 0.15, MeOH); UV (MeOH) λ~max~ 219 nm; ^1^H and ^13^C NMR data, [Table 2](#marinedrugs-18-00129-t002){ref-type="table"}; HRESIMS *m/z* 319.1518 \[M + Na\]^+^ (C~16~H~24~O~5~Na, calcd.319.1516).

*Pestalotheol O* (**7**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ +35 (*c* 0.22, MeOH); UV (MeOH) λ~max~ 218 nm; ^1^H and ^13^C NMR data, [Table 3](#marinedrugs-18-00129-t003){ref-type="table"}; HRESIMS *m/z* 361.1619 \[M + Na\]^+^ (C~18~H~26~O~6~Na, calcd. 361.1622).

*Pestalotheol P* (**8**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ +89 (*c* 0.22, MeOH); UV (MeOH) λ~max~ 282 nm; ^1^H and ^13^C NMR data, [Table 3](#marinedrugs-18-00129-t003){ref-type="table"}; HRESIMS *m/z* 329.1595 \[M + H\]^+^ (C~16~H~25~O~7~, calcd. 329.1595).

*Pestalotheol Q* (**9**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ +121 (*c* 0.15, MeOH); UV (MeOH) λ~max~ 279 nm; ^1^H and ^13^C NMR data, [Table 3](#marinedrugs-18-00129-t003){ref-type="table"}; HRESIMS *m/z* 355.1754 \[M + H\]^+^ (C~18~H~27~O~7~, calcd. 355.1757).

*Cytosporin O* (**15**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ −8 (*c* 0.30, MeOH); UV (MeOH) λ~max~ 243 nm; ^1^H and ^13^C NMR data, [Table 4](#marinedrugs-18-00129-t004){ref-type="table"}; HRESIMS *m/z* 363.2144 \[M + Na\]^+^ (C~19~H~32~O~5~Na, calcd. 363.2142).

*Cytosporin P* (**16**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ −4 (*c* 0.35, MeOH); UV (MeOH) λ~max~ 240 nm; ^1^H and ^13^C NMR data, [Table 4](#marinedrugs-18-00129-t004){ref-type="table"}; HRESIMS *m/z* 379.2094 \[M + Na\]^+^ (C~19~H~32~O~6~Na, calcd. 379.2091).

*Cytosporin Q* (**17**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ +16 (*c* 0.22, MeOH); UV (MeOH) λ~max~ 237 nm; ^1^H and ^13^C NMR data, [Table 4](#marinedrugs-18-00129-t004){ref-type="table"}; HRESIMS *m/z* 356.2432 \[M + NH~4~\]^+^ (C~19~H~34~O~5~N, calcd. 356.2431).

*Cytosporin R* (**18**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ +6 (*c* 0.20, MeOH); UV (MeOH) λ~max~ 239 nm; ^1^H and ^13^C NMR data, [Table 5](#marinedrugs-18-00129-t005){ref-type="table"}; HRESIMS *m/z* 355.2117 \[M + H\]^+^ (C~19~H~31~O~6~, calcd. 355.2121).

*Cytosporin S* (**19**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ +14 (c 0.10, MeOH); UV (MeOH) λ~max~ 239 nm; ^1^H and ^13^C NMR data, [Table 5](#marinedrugs-18-00129-t005){ref-type="table"}; HRESIMS *m/z* 377.1934 \[M + Na\]^+^ (C~19~H~30~NaO~6~, calcd. 377.1935).

*Cytosporin T* (**20**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ −1 (*c* 0.20, MeOH); UV (MeOH) λ~max~ 238 nm; ^1^H and ^13^C NMR data, [Table 5](#marinedrugs-18-00129-t005){ref-type="table"}; HRESIMS *m/z* 377.1931\[M + Na\]^+^ (C~19~H~30~O~6~Na, calcd. 377.1935).

*Cytosporin U* (**21**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ + 4 (c 0.20, MeOH); UV (MeOH) λ~max~ 237 nm; ^1^H and ^13^C NMR data, [Table 6](#marinedrugs-18-00129-t006){ref-type="table"}; HRESIMS m/z 372.2381\[M + NH~4~\]^+^ (C~19~H~34~NO~6~, calcd. 372.2381), 377.1935 \[M + Na\]^+^ (C~19~H~30~O~6~Na, calcd. 377.1935).

*Cytosporin V* (**22**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ −21 (*c* 0.30, MeOH); UV (MeOH) λ~max~ 237 nm; ^1^H and ^13^C NMR data, [Table 6](#marinedrugs-18-00129-t006){ref-type="table"}; HRESIMS *m/z* 398.2537\[M + NH~4~\]^+^ (C~21~H~36~NO~6~, calcd. 398.2537), 403.2089 \[M + Na\]^+^ (C~21~H~32~O~6~Na, calcd. 403.2091).

*Cytosporin W* (**23**): colorless oil; $\left\lbrack \alpha \right\rbrack_{D}^{20}$ −4 (*c* 0.10, MeOH); UV (MeOH) λ~max~ 215, 281 nm; ^1^H and ^13^C NMR data, [Table 6](#marinedrugs-18-00129-t006){ref-type="table"}; HRESIMS *m/z* 359.1829 \[M + Na\]^+^ (C~19~H~28~O~5~Na, calcd. 359.1829).

3.4. Preparation of (R)- and (S)-MTPA Esters {#sec3dot4-marinedrugs-18-00129}
--------------------------------------------

Compound **1** (0.8 mg) was dissolved in prydine-*d*~6~ (500 μL) and then transferred to an NMR tube. (*S*)-MTPACl (10.0 µL, 0.050 mmol) was added quickly. By shaking the NMR tube, the reagent and the dissolved compound were mixed. After 10 h at room temperature, ^1^H NMR data were obtained for the (*R*)-MTPA ester (**1a**). Following the same protocol, the (*S*)-MTPA ester (**1b**) was produced. A similar procedure was applied for compound **8**.

3.5. Preparation of Compound 17a {#sec3dot5-marinedrugs-18-00129}
--------------------------------

Compound **17** (10 mg, 0.030 mmol) was dissolved in anhydrous CH~2~Cl~2~ (3 mL) together with catalytic amount of DMAP and 10.0 mg of 4,4′-dimethoxytrytil chloride (0.030 mmol, DMTCl) at room temperature for 2 h. After removal of the solvent, preparative thin-layer chromatography was used for purification, using CH~2~Cl~2~-MeOH (95:5), to give compound **17a**.

3.6. Preparation of (R)- and (S)-MPA Esters {#sec3dot6-marinedrugs-18-00129}
-------------------------------------------

Compound **7** (0.8 mg, 0.002 mmol), along with DMAP (0.5 mg, 0.004 mmol), *N*,*N*′-dicyclohexylcarbodiimide (0.8 mg, 0.004 mmol, DCC) and (*R*)-MPA (0.7 mg, 0.004 mmol), was mixed in anhydrous CH~2~Cl~2~ (0.3 mL). The solvent was removed after 2 h at room temperature. The (*R*)-MPA ester (**7a**) was obtained from the crude product by semipreparative HPLC (MeOH-H~2~O: 0-2 min, 40%; 2--15 min; 15--25 min, 100%). Following a similar procedure, the (*S*)-MPA ester (**7b**) was obtained by using (*S*)-MPA. The above steps were also applied to compounds **17a**, **18**, **25,** and **26**.

3.7. Cytotoxicity and Antibacterial Assay {#sec3dot7-marinedrugs-18-00129}
-----------------------------------------

The MTT method was applied for the cytotoxicity assay against the mouse lymphoma cell line L5178Y as described before \[[@B24-marinedrugs-18-00129]\]. Antibacterial activity against Gram-positive bacteria *Staphylococcus aureus* (ATCC 29213) and *Mycobacterium tuberculosis* (H37Rv), and the Gram-negative bacteria *Pseudomonas aeruginosa* (ATCC 27853) and drug-resistant *Acinetobacter baumannii* (ATCC BAA-1605), was evaluated using the microdilution method in alignment with the CLSI guidelines using Muller Hinton broth for bacteria and 7H9 broth for Mycobacteria \[[@B25-marinedrugs-18-00129]\]. Additionally, the antibacterial activity was performed in combination with sublethal concentrations of the antibiotic colistin (0.1 µM) for drug-resistant *A. baumannii* (ATCC BAA-1605) to elucidate synergistic effects of the combinatory therapy.
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###### 

NMR Data of compounds **1**--**3**.

  -------------------------------------------------------------------------------------------------------------------------------------
  No.     1 *^a^*       2 *^a,c^*                     3 *^b^*                                                  
  ------- ------------- ----------------------------- ------------- ---------------------------- ------------- ------------------------
  2       84.2, CH      3.95, dd (9.9, 6.4)           84.1, CH      3.57, dd (8.3, 5.7)          86.0, CH      4.07, dd (9.4, 6.7)

  3       34.0, CH~2~   2.20, dd (12.4, 9.9)\         36.1, CH~2~   2.08, dd (13.5, 8.3)\        31.0, CH~2~   2.55, dd, (13.3, 9.4)\
                        1.60, dd (12.4, 6.4)                        1.81, dd (13.5, 5.7)                       1.72, dd, (13.3, 6.7)

  4       77.8, C                                     82.5, C                                    69.5, C       

  5       68.9, CH      4.05, dd (5.3, 4.6)           72.3, CH      4.24, dd (5.0, 2.5)          60.1, CH      3.75, d (2.8)

  6       138.0, CH     6.71, dd (4.6, 2.3)           141.0, CH     6.69, t (2.5)                64.6, CH      4.65, dd (8.8, 2.8)

  7       138.7, C                                    137.8, C                                   135.5, C      

  8       25.7, CH~2~   2.53, dd (16.0, 5.3)\         26.8, CH~2~   2.54, dd (16.9, 3.9)\        35.4, CH~2~   2.50, dd (12.1, 11.5)\
                        2.09, ddd (16.0, 10.7, 2.3)                 2.14, ddd (16.9, 5.4, 2.5)                 2.21, dd, (12.1, 4.8)

  9       76.3, CH      3.63, dd (10.7, 5.3)          82.7, CH      4.05, dd (5.4, 3.9)          77.7, CH      3.86, dd (11.5, 4.8)

  10      191.9, C                                    190.1, C                                   127.6, CH     6.25, d (11.7)

  11      120.7, CH     6.57, s                       120.0, CH     6.59, s                      122.8, CH     6.29, d (11.7)

  12      153.7, C                                    153.6, C                                   139.9, C      

  13      20.5, CH~3~   2.00, s                       20.5, CH~3~   2.00, s                      60.9, CH~2~   4.21, dd (12.5, 5.3)\
                                                                                                               4.16, dd (12.5, 5.3)

  14      27.2, CH~3~   1.90, s                       27.1, CH~3~   1.90, s                      22.0, CH~3~   1.85, s

  15      70.8, C                                     70.9, C                                    71.9, C       

  16      25.8, CH~3~   1.07, s                       26.0, CH~3~   1.09, s                      26.6, CH~3~   1.23, s

  17      25.9, CH~3~   1.01, s                       26.7, CH~3~   0.99, s                      25.8, CH~3~   1.09, s

  4-OH                  4.54, s                                     5.37, s                                    

  5-OH                  5.38, d (5.3)                               5.52, d (5.0)                              

  6-OH                                                                                                         3.97, d (8.8)

  13-OH                                                                                                        3.70, t (5.3)

  15-OH                 4.16, s                                     4.75, s                                    3.34, s
  -------------------------------------------------------------------------------------------------------------------------------------

^a^ Recorded at 600 MHz (^1^H) and 150 MHz (^13^C) in DMSO-*d*~6~. ^b^ Recorded at 600 MHz (^1^H) and 150 MHz (^13^C) in Acetone-*d*~6~. ^c^ Data extracted from the HSQC and HMBC spectra.
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###### 

NMR Data of compounds **4**--**6**.

  ------------------------------------------------------------------------------------------------------------------------------------
  No.     4 *^a^*        5 *^a,b^*               6 *^a^*                                                
  ------- -------------- ----------------------- -------------- ------------------------ -------------- ------------------------------
  2       85.2, CH       3.73, dd (8.1, 7.7)     84.6, CH       4.01, dd (9.6, 6.4)      83.7, CH       3.86, dd (9.9, 6.3)

  3       37.5, CH~2~    2.43, dd (13.0, 7.7)\   33.5, CH~2~    2.12, (dd, 12.0, 9.6)\   34.1, CH~2~    2.12, dd (12.0, 9.9)\
                         1.79, dd (13.0, 8.1)                   1.59, dd, (12.0, 6.4)                   1.53, dd (12.0, 6.3)

  4       79.1, C                                76.4, C                                 79.8, C        

  5       71.8, CH       3.60, t (4.0)           72.5, CH       3.81, d (3.7)            71.1, CH       3.83, d (3.8)

  6       67.6, CH       4.11, dd (9.0, 4.0)     74.1, CH       3.73, d (9.1)            74.9, CH       4.01, s

  7       124.1, C                               122.2, C                                102.2, C       

  8       134.0, CH      5.87, d (3.2)           132.9, CH      6.10, d (1.7)            27.8, CH~2~    2.52, ddd (12.4, 11.9, 3.9)\
                                                                                                        2.23, dd (11.9, 4.4)

  9       81.2, CH       4.10, d (3.2)           77.1, CH       4.35, d (1.7)            77.4, CH       3.81, dd (12.4, 4.4)

  10      88.6, C                                88.8, C                                 204.6, C       

  11      90.2, C                                88.7, C                                 95.7, CH       5.92, d (3.9)

  12      126.4, C                               126.0, C                                139.0, C       

  13      122.1, CH~2~   5.32, s\                121.6, CH~2~   5.30, s\                 113.5, CH~2~   4.93, s\
                         5.27, s                                5.26, s                                 4.82, s

  14      23.2, CH~3~    1.87, s                 23.0, CH~3~    1.87, s                  19.5, CH~3~    1.69, s

  15      70.2, C                                70.5, C                                 70.5, C        

  16      25.9, CH~3~    1.07, s                 25.8, CH~3~    1.10, s                  26.1, CH~3~    1.07, s

  17      26.4, CH~3~    1.00, s                 25.5, CH~3~    0.99, s                  25.9, CH~3~    0.98, s

  4-OH                   5.05, s                                4.68, s                                 5.22, s

  5-OH                   4.77, d (4.0)                          5.47, d (3.7)                           5.28, d (3.8)

  6-OH                   5.08, d (9.0)                          4.72, d (9.1)                           5.74, br s

  15-OH                  4.31, s                                4.23, s                                 4.17, s
  ------------------------------------------------------------------------------------------------------------------------------------

^a^ Recorded at 600 MHz (^1^H) and 150 MHz (^13^C) in DMSO-*d*~6~. ^b^ Data extracted from the HSQC and HMBC spectra.
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###### 

NMR Data of compounds **7**--**9**.

  ------------------------------------------------------------------------------------------------------------------------------------
  No.     7 *^a^*        8 *^b^*                         9 *^a,c^*                                             
  ------- -------------- ------------------------------- ------------- ------------------------ -------------- -----------------------
  2       83.5, CH       3.88, dd (9.6, 6.4)             86.1, CH      4.13, dd (10.1, 6.4)     84.4, CH       3.95, dd (9.5, 6.5)

  3       34.0, CH       1.83, dd (12.3, 9.6)\           35.0, CH~2~   2.49, dd (12.5, 10.1)\   33.9, CH~2~    1.80, dd (12.5, 9.5)\
                         1.62, dd (12.3, 6.4)                          1.77, dd (12.5, 6.4)                    1.66, dd (12.5, 6.5)

  4       77.8, C                                        80.1, C                                76.4, C        

  5       72.0, CH       5.01, d (2.5)                   72.2, CH      4.08, d (5.1)            71.3, CH       5.28, s

  6       71.7, CH       4.04, d (2.5)                   168.3, C                               162.3, C       

  7       101.5, C                                       107.0, C                               110.0, C       

  8       27.4, CH~2~    2.56, ddd (12.4, 12.0, 3.9,)\   22.4, CH~2~   2.70, dd (14.9, 5.7)\    21.3, CH~2~    2.55, dd (14.9, 5.5)\
                         2.31, dd (12.0, 4.4)                          2.11 (dd, 14.9, 10.6)                   2.01, dd (14.9, 10.7)

  9       78.0, CH       3.76, dd (12.4. 4.4)            76.9, CH      3.91, dd (10.6, 5.7)     76.5, CH       3.63, dd (10.7, 5.5)

  10      204.4, CH                                      194.6, C                               191.9, C       

  11      96.5, CH       6.02, d (3.9)                   76.1, CH      4.13, d (2.8)            46.4, CH~2~    2.65, d (16.7)\
                                                                                                               2.42, d (16.7)

  12      138.2, C                                       84.4, C                                80.4, C        

  13      114.5, CH~2~   4.99, s\                        26.9, CH~3~   1.49, s                  27.3, CH~3~    1.36, s
                         4.88, s                                                                               

  14      19.5, CH~3~    1.71, s                         16.5, CH~3~   1.14, s                  23.4, CH~3~    1.24, s

  15      70.5, C                                        72.0, C                                70.5, C        

  16      25.9, CH~3~    1.09, s                         26.7, CH~3~   1.18, s                  26.1, CH~3~    0.99, s

  17      26.0, CH~3~    0.98, s                         25.6, CH~3~   1.09, s                  25.6, CH~3~    1.08, s

  4-OH                   5.45, s                                       3.97, s                                 5.31, s

  5-OH                                                                 5.09, d (5.1)                           

  6-OH                   5.91, br s                                                                            

  11-OH                                                                4.30, d (2.8)                           

  13-OH                  4.24, s                                                                               

  15-OH                                                                3.22, s                                 4.25, s

  5-OAc   20.6, CH~3~\   2.00, s                                                                20.5, CH~3~\   2.09, s
          169.2, C                                                                              169.5, C       
  ------------------------------------------------------------------------------------------------------------------------------------

^a^ Recorded at 600 MHz (^1^H) and 150 MHz (^13^C) in DMSO-*d*~6~. ^b^ Recorded at 600 MHz (^1^H) and 150 MHz (^13^C) in Acetone-*d*~6~. ^c^ Data extracted from the HSQC and HMBC spectra.
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###### 

NMR Data of compounds **15**--**17**.

  --------------------------------------------------------------------------------------------------------------------------
  No.     15 *^a^*      16 *^a^*                17 *^b^*                                            
  ------- ------------- ----------------------- ------------- ----------------------- ------------- ------------------------
  2       74.9, C                               75.0, C                               75.4, C       

  3       70.6, CH      3.20, dt (12.0, 4.9)    69.8, CH      3.78, dt (11.4, 5.5)    72.1, CH      3.38, dt (11.7, 5.0)

  4       42.7, CH~2~   1.75, dd (12.8, 4.9)\   42.3, CH~2~   2.00, dd (13.2, 5.5)\   35.8, CH~2~   2.04, dd (12.7, 11.7)\
                        1.65, dd (12.8, 12.0)                 1.68, dd (13.2, 11.4)                 1.50, dd (12.7, 5.0)

  5       69.3, C                               69.2, C                               58.1, C       

  6       35.7, CH~2~   2.00, dd (13.9, 4.3)\   75.3, CH      3.55, d (8.0)           61.8, CH      3.24, d (2.7)
                        1.54, d (13.9)                                                              

  7       63.9, CH      4.30, dd (7.6, 4.3)     69.5, CH      4.11, d (7.6)           64.8, CH      4.47, dd (7.3, 2.7)

  8       133.8, C                              131.8, C                              132.9, C      

  9       132.0, C                              131.7, C                              130.0, C      

  10      70.0, CH      3.87, s                 70.1, CH      4.01, s                 65.4, CH      4.34, s

  11      27.9, CH~3~   1.07, s                 27.7, CH~3~   1.06, s                 27.7, CH~3~   1.12, s

  12      16.1, CH~3~   1.10, s                 16.4, CH~3~   1.13, s                 16.1, CH~3~   1.16, s

  13      57.7, CH~2~   4.21, dd (11.9, 4.0)\   57.5, CH~2~   4.24, dd (11.9, 4.2)\   58.0, CH~2~   4.09, br d (11.6)\
                        3.81, dd (11.9, 6.2)                  3.92, dd (11.9, 6.2)                  3.79, br d (11.6)

  14      126.0, CH     6.36, d (15.7)          126.4, CH     6.44, d (15.8)          124.9, CH     6.06, d (15.8)

  15      132.1, CH     5.90, dt (15.7, 7.0)    132.1, CH     5.91, dt (15.8, 7.0)    134.5, CH     5.85, dt (15.8, 6.8)

  16      32.8, CH~2~   2.10, m                 32.8, CH~2~   2.12, m                 33.0, CH~2~   2.06, m

  17      28.6, CH~2~   1.37, m                 28.6, CH~2~   1.38, m                 28.5, CH~2~   1.36, m

  18      30.8, CH~2~   1.27, m                 30.8, CH~2~   1.27, m                 30.8, CH~2~   1.27, m

  19      22.0, CH~2~   1.29, m                 22.0, CH~2~   1.29, m                 22.0, CH~2~   1.28, m

  20      13.9, CH~3~   0.86, t (6.9)           13.9, CH~3~   0.87, t (6.9)           13.9, CH~3~   0.86, t (7.0)

  3-OH                  4.76, d (4.9)                         4.70, d (5.5)                         5.05, d (5.0)

  5-OH                  5.07, s                               5.16, s                               

  6-OH                                                        3.98, d (8.0)                         

  7-OH                  4.75, d (7.6)                         4.88, d (7.6)                         4.92, d (7.3)

  13-OH                 4.53, dd (6.2, 4.0)                   4.54, dd (6.2, 4.2)                   4.55, br s
  --------------------------------------------------------------------------------------------------------------------------

^a^ Recorded at 600 MHz (^1^H) and 150 MHz (^13^C) in DMSO-*d*~6~. ^b^ Recorded at 300 MHz (^1^H) and 75 MHz (^13^C) in DMSO-*d*~6~.
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###### 

NMR Data of compounds **18**--**20**.

  ---------------------------------------------------------------------------------------------------------------------------
  No.     18 *^a^*      19 *^b,c^*              20 *^b,c^*                                           
  ------- ------------- ----------------------- ------------- ------------------------ ------------- ------------------------
  2       75.4, C                               75.2, C                                75.2, C       

  3       72.1, CH      3.39, m                 71.8, CH      3.38, dt (11.8, 5.0)     71.8, CH      3.38, dt (11.8, 4.9)

  4       35.8, CH~2~   2.04, m\                35.5, CH~2~   2.05, dd (12.6, 11.8)\   35.5, CH~2~   2.05, dd (12.7, 11.8)\
                        1.50, dd (12.7, 5.0)                  1.50, dd (12.6, 5.0)                   1.50, dd (12.7, 4.9)

  5       58.1, C                               57.7, C                                57.7, C       

  6       61.8, CH      3.24, d (2.5)           61.5, CH      3.25, d (2.6)            61.5, CH      3.25, d (2.5)

  7       64,8, CH      4.48, dd (7.6, 2.5)     64.5, CH      4.48, dd (7.4, 2.6)      64.4, CH      4.49, d (7.5, 2.5)

  8       132.9, C                              132.5, C                               132.3, C      

  9       130.0, C                              129.8, C                               130.4, C      

  10      65.4, CH      4.34, s                 65.1, CH      4.34, s                  65.0, CH      4.35, s

  11      27.7, CH~3~   1.12, s                 27.5, CH~3~   1.12, s                  27.4, CH~3~   1.12, s

  12      16.1, CH~3~   1.16, s                 15.8, CH~3~   1.16, s                  15.8, CH~3~   1.16, s

  13      58.0, CH~2~   4.09, dd (12.0, 2.0)\   57.7, CH~2~   4.11, dd (11.9, 2.3)\    57.6, CH~2~   4.12, dd (11.9, 2.0)\
                        3.79, dd (12.0, 3.5)                  3.79, dd (11.9, 4.2)                   3.79, dd (11.9, 4.0)

  14      124.9, CH     6.06, d (15.9)          126.2, CH     6.08, d (16.0)           122.8, CH     6.20, d (16.0)

  15      134.6, CH     5.85, dt (15.9, 7.0)    131.4, CH     5.88, dt (16.0, 7.2)     137.8, CH     5.86, dd (16.0, 6.2)

  16      33.1, CH~2~   2.05, m                 41.5, CH~2~   2.15, m                  71.0, CH~2~   3.95, m

  17      25.2, CH~2~   1.40, m\                69.2, CH      3.46, m                  36.9, CH~2~   1.40, m
                        1.34, m                                                                      

  18      38.5, CH~2~   1.33, m\                38.4, CH~2~   1.36, m\                 27.0, CH~2~   1.28, m
                        1.30, m                               1.27, m                                

  19      65.6, CH      3.57, m                 18.1, CH~2~   1.38, m\                 21.9, CH~2~   1.27, m
                                                              1.27, m                                

  20      23.7, CH~3~   1.03, d (6.1)           13.8, CH~3~   0.85, t (6.9)            13.7, CH~3~   0.86, t (6.9)

  3-OH                  5.06, d (4.5)                         5.07, d (5.0)                          5.07, d (4.9)

  7-OH                  4.94, d (7.6)                         4.92, d (7.4)                          4.94, d (7.5)

  13-OH                 4.56, dd (3.5, 2.0)                   4.56, dd (4.2, 2.3)                    4.58, dd (4.0, 2.0)

  16-OH                                                                                              4.62, d (4.0)

  17-OH                                                       4.34, br s                             

  19-OH                 4.31, d (4.3)                                                                
  ---------------------------------------------------------------------------------------------------------------------------

^a^ Recorded at 300 MHz (^1^H) and 75 MHz (^13^C) in DMSO-*d*~6~. ^b^ Recorded at 600 MHz (^1^H) and 150 MHz (^13^C) in DMSO-*d*~6~. ^c^ Data extracted from the HSQC and HMBC spectra.
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###### 

NMR Data of compounds **21**--**23**.

  -------------------------------------------------------------------------------------------------------------------------------------------------
  No.     21 *^a^*      22 *^b^*                 23 *^b,c^*                                                                
  ------- ------------- ------------------------ -------------- -------------------------------------------- ------------- ------------------------
  2       75.4, C                                75.7, C                                                     76.7, C       

  3       72.0, CH      3.39, dt (11.8, 4.9)     71.8, CH       3.42, dt (11.8, 4.9)                         71.9, CH      3.45, dt (11.6, 5.0)

  4       35.8, CH~2~   2.05, dd (12.6, 11.8)\   35.2, CH~2~    2.06, dd (12.7, 11.8) 1.53, dd (12.7, 4.9)   34.0, CH~2~   2.21, dd (12.8, 11.6)\
                        1.50, dd (12.6, 4.9)                                                                               1.63, dd (12.8, 5.0)

  5       57.9, C                                58.0, C                                                     61.1, C       

  6       61.7, CH      3.25, d (2.3)            58.1, CH       3.39, d (2.8)                                59.3, CH      3.54, d (1.2)

  7       64.8, CH      4.48, dd (7.3, 2.3)      67.6, CH       5.85, d (2.8)                                195.8, C      

  8       132.5, C                               128.0, C                                                    130.3, C      

  9       130.7, C                               133.4, C                                                    148.2, C      

  10      65.3, CH      4.35, s                  64.7, CH       4.40, s                                      64.5, CH      4.74, d (1.2)

  11      27.7, CH~3~   1.12, s                  27.6, CH~3~    1.13, s                                      27.5, CH~3~   1.16, s

  12      16.1, CH~3~   1.16, s                  16.1, CH~3~    1.17, s                                      16.1, CH~3~   1.24, s

  13      58.0, CH~2~   4.12, dd (11.8, 4.1)\    57.6, CH~2~    4.11, dd (12.0, 4.4)\                        58.1, CH~2~   4.26, dd (13.5, 2.1)\
                        3.79, dd (11.8, 5.0)                    3.78, dd (12.0, 5.8)                                       4.02, dd (13.5, 4.5)

  14      123.3, CH     6.18, d (16.0)           123.8, CH      6.04, d (16.1)                               120.6, CH     6.04, m

  15      138.2, CH     5.86, dd (16.0, 6.1)     133.9, CH      5.49, dt (16.1, 7.0)                         138.4, CH     6.03, m

  16      71.3, CH      3.94, m                  32.6, CH~2~    2.04, m                                      33.0, CH~2~   2.10, m

  17      37.1, CH~2~   1.40, m\                 28.4, CH~2~    1.32, m                                      28.2, CH~2~   1.37, m
                        1.34, m                                                                                            

  18      27.2, CH~2~   1.27, m                  30.6, CH~2~    1.23, m                                      30.7, CH~2~   1.26, m

  19      22.2, CH~2~   1.25, m                  21.9, CH~2~    1.27, m                                      21.9, CH~2~   1.28, m

  20      14.0, CH~3~   0.86, t (6.9)            13.9, CH~3~    0.86, t (6.8)                                13.9, CH~3~   0.86, t (7.0)

  3-OH                  5.07, d (4.9)                           5.12, d (4.9)                                              5.26, d (5.0)

  7-OH                  4.91, d (7.3)                                                                                      

  13-OH                 4.57, dd (5.0, 4.1)                     4.73, dd (5.8, 4.4)                                        5.17, dd (4.5, 2.1)

  16-OH                 4.64, d (4.5)                                                                                      

  7-OAc                                          20.6, CH~3~\   2.02, s                                                    
                                                 170.0, C                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Recorded at 300 MHz (^1^H) and 75 MHz (^13^C) in DMSO-*d*~6~. ^b^ Recorded at 600 MHz (^1^H) and 150 MHz (^13^C) in DMSO-*d*~6~. ^c^ Data extracted from the HSQC and HMBC spectra.
